发布求助
文献互助 智能选刊 最新文献

特发性肺纤维化的治疗：二期和三期临床试验中新出现药物的最新情况

IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Expert Opinion on Emerging Drugs Pub Date : 2024-04-08 DOI:10.1080/14728214.2024.2340723
Sarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, Martin Kolb
{"title":"特发性肺纤维化的治疗：二期和三期临床试验中新出现药物的最新情况","authors":"Sarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, Martin Kolb","doi":"10.1080/14728214.2024.2340723","DOIUrl":null,"url":null,"abstract":"Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating lung disease with poor prognosis. Although two antifibrotics have been approved in the past decade there are no curative therapies...","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"46 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials\",\"authors\":\"Sarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, Martin Kolb\",\"doi\":\"10.1080/14728214.2024.2340723\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating lung disease with poor prognosis. Although two antifibrotics have been approved in the past decade there are no curative therapies...\",\"PeriodicalId\":12292,\"journal\":{\"name\":\"Expert Opinion on Emerging Drugs\",\"volume\":\"46 1\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Emerging Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14728214.2024.2340723\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Emerging Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728214.2024.2340723","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

特发性肺纤维化（IPF）是一种进行性肺部疾病，使人衰弱，预后不良。尽管在过去十年中已经批准了两种抗纤维化药物，但目前还没有治愈的疗法......
本文章由计算机程序翻译，如有差异，请以英文原文为准。
分享
查看原文 本刊更多论文
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating lung disease with poor prognosis. Although two antifibrotics have been approved in the past decade there are no curative therapies...
求助全文
通过发布文献求助，成功后即可免费获取论文全文。 去求助
来源期刊
Expert Opinion on Emerging Drugs
Expert Opinion on Emerging Drugs 医学-药学
CiteScore
5.90
自引率
0.00%
发文量
28
审稿时长
>12 weeks
期刊介绍： Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信